The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study
- 16 December 2015
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 25 (3) , 297-306
Abstract
The availability of accurate product-specific exposure information is essential in the pharmacovigilance of biologicals, because differences in the safety profile may emerge between products containing the same active substance. In spontaneous adverse drug reaction (ADR) reports, drug exposure may, however, be misclassified, that is, attributed to the incorrect product. The aim of this study was to explore the effect of exposure misclassification on the time to detection of product-specific risks in spontaneous reporting systems. We used data simulations to explore the effect of exposure misclassification. We simulated an active substance-specific subset of a spontaneous reporting system and used the proportional reporting ratio for signal detection. The effect of exposure misclassification was evaluated in three test cases representing product-specific ADRs that may occur for biologicals and studied in relative terms by varying the model parameters (market share and relative risk). We found that exposure misclassification results in the largest delay in identification of risks that have a weak association (relative risk < 2 or 3) with the product of interest and in situations where the product associated with the unique risk has a large (>50%) market share. The absolute public health impact of exposure misclassification, in terms of cases/time to detection, varied considerably across the test cases. Exposure misclassification in ADR reports may result in a delayed detection of product-specific risks, particularly in the detection of weak drug-event associations. Our findings can help inform the future implementation and refinement of product-specific and batch-specific signal detection procedures.Keywords
Funding Information
- College ter Beoordeling van Geneesmiddelen
This publication has 38 references indexed in Scilit:
- Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of ImmunogenicityPharmaceutical Research, 2011
- Developing the Nation's Biosimilars ProgramNew England Journal of Medicine, 2011
- Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the NetherlandsDrug Safety, 2010
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Under-Reporting of Adverse Drug ReactionsDrug Safety, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under‐reporting on odds ratiosStatistics in Medicine, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002